Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NQO2 | P16083 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3858045 | 0.83 | ALDH1A3 (0.45) | RAB9AALDH1A1ALDH1A3LMNAMAPT | |
| Benzaldehyde SCHEMBL367504 | 0.80 | ALDH1A1 (0.54) | ALDH1A1RELAALDH1A3L3MBTL1TYR | |
| SCHEMBL372348 | 0.80 | KDM4E (0.48) | RAB9AALDH1A1GAAL3MBTL1LMNA | |
| 2-Naphthaldehyde SCHEMBL28110154 | 0.79 | RELA (0.58) | RAB9ANQO2ALDH1A1RELAPTGS1 | |
| 2-Naphthaldehyde SCHEMBL30229844 | 0.79 | RELA (0.58) | RAB9ANQO2ALDH1A1RELAPTGS1 | |
| 2-Naphthaldehyde SCHEMBL51340 | 0.79 | RELA (0.58) | RAB9ANQO2ALDH1A1RELAPTGS1 | |
| 2-Naphthaldehyde SCHEMBL27347080 | 0.79 | RELA (0.58) | RAB9ANQO2ALDH1A1RELAPTGS1 | |
| SCHEMBL27914859 | 0.79 | NQO2 (0.45) | NQO2ALDH1A1RELAPTGS1GAA | |
| Ethylene SCHEMBL6226363 | 0.78 | LMNA (0.48) | ALDH1A1ALDH1A3TYRLMNAMAPT | |
| SCHEMBL9632142 | 0.78 | MAOA (0.49) | RAB9AALDH1A1PTGS1TDP1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317490-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A., (ES) | 2021-10-14 | — | — | US | disclosed |
| EP-3640236-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2020-04-22 | — | — | EP | disclosed |
| CN-110650954-A | Anticancer compounds | 法马马有限公司 | 2020-01-03 | — | — | CN | disclosed |
| EP-2595948-B1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LTD (IE) | 2019-09-04 | — | — | EP | disclosed |
| WO-2018167270-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2018-09-20 | — | — | WO | disclosed |
| EP-3004036-B1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LTD (IE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2864290-B1 | 3-O-HETEROARYL-INGENOL | LEO LABORATORIES LTD (IE) | 2017-06-14 | — | — | EP | disclosed |
| US-9676698-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2017-06-13 | — | — | US | disclosed |
| US-20160280627-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2016-09-29 | — | — | US | disclosed |
| US-9422309-B2 | 3-O-heteroaryl-ingenol | LEO LABORATORIES LIMITED (IE) | 2016-08-23 | — | — | US | disclosed |
| EP-2864290-A2 | 3-O-HETEROARYL-INGENOL | Leo Laboratories Limited (IE) | 2015-04-29 | — | — | EP | disclosed |
| CN-104411685-A | 3-o-heteroaryl-ingenol | LEO LAB LTD | 2015-03-11 | — | — | CN | disclosed |
| WO-2014191457-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LIMITED (IE) | 2014-12-04 | — | — | WO | disclosed |
| US-8901356-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2014-12-02 | — | — | US | disclosed |
| WO-2014108526-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF PIPECOLIDEPSIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014001215-A2 | 3-O-HETEROARYL-INGENOL | LEO LABORATORIES LIMITED (IE) | 2014-01-03 | — | — | WO | disclosed |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | Hogberg, Thomas (DK) | 2013-07-11 | — | — | US | disclosed |
| EP-2595948-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2013-05-29 | — | — | EP | disclosed |
| CN-103119016-A | Method for preparing ingenol-3-angelate | LEO PHARMA AS | 2013-05-22 | — | — | CN | disclosed |
| WO-2012010172-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO PHARMA A/S (DK) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317490-A1 | ANTICANCER COMPOUNDS | SLC75A1, SLC15A1, LCT | RAB9A 1871/4885NQO2 1188/4885ALDH1A1 947/4885 |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | RAB9A 2498/4885NQO2 514/4885ALDH1A1 1005/4885 |
| US-20160280627-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | RAB9A 2498/4885NQO2 514/4885ALDH1A1 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.